Form 4: Disc Medicine Director Kevin Bitterman Reports Pre-Planned Stock Sales

Disc Medicine, Inc. Director Kevin Bitterman reported the sale of 42,870 shares of common stock in pre-scheduled transactions in late July 2025.

Summary

• Director Kevin Bitterman sold a total of 42,870 shares of Disc Medicine, Inc. common stock across two transactions on July 23, 2025, and July 24, 2025.
• On July 23, 2025, 29,837 shares were sold at a weighted average price of $60.97 per share, with prices ranging from $60.95 to $61.10.
• On July 24, 2025, an additional 13,033 shares were sold at a weighted average price of $61.17 per share, with prices ranging from $60.95 to $61.55.
• These transactions were conducted pursuant to a Rule 10b5-1(c) pre-planned trading arrangement.
• Following these sales, Kevin Bitterman indirectly beneficially owns 633,969 shares through Atlas Venture Opportunity Fund I, LP, 420,549 shares through Atlas Venture Opportunity Fund II, LP, and 51,000 shares through Atlas Venture Fund XII, L.P.

Sentiment

Score: 5

Explanation: The filing reports pre-planned insider sales, which are neutral in sentiment as they are not typically reactive to new company performance or events. While any insider sale can be viewed with caution, the Rule 10b5-1 plan mitigates immediate negative implications.

Negatives

• A director of the company sold a significant number of shares, which can sometimes be perceived negatively by investors, although these sales were pre-planned.

Related Party Transactions

• The reported sales of common stock by Kevin Bitterman, a Director of Disc Medicine, Inc., constitute related party transactions.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a signal, though the pre-planned nature of the sales under Rule 10b5-1 suggests it is not based on new, undisclosed information.

Key Dates

Recommendation

The filing is a factual report of pre-planned insider stock sales by a director. While insider sales are a data point for investors, the fact that these transactions were executed under a Rule 10b5-1 plan suggests they were scheduled in advance and not necessarily indicative of a change in the director's outlook on the company's immediate prospects. Without additional financial or operational context, a 'hold' recommendation is appropriate, advising investors to consider this information as part of a broader analysis rather than a standalone signal for a strong buy or sell.

Keywords

Disc Medicine, IRON, Insider Sale, Form 4, Director Transaction, Equity Sale, Kevin Bitterman, Rule 10b5-1, Biotechnology